Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Spondyloarthritis
•
Psoriatic arthritis
•
General Rheumatology
•
Cardiology
•
Cardio-Rheumatology
•
Pericarditis
In a patient with psoriatic arthritis and recurrent pericarditis, would you combine abatacept or other biologics with rilonacept?
Related Questions
What would be the minimum duration of IL-1 therapy you would recommend for chronic pericarditis?
How do you approach management of recurrent idiopathic pleuropericarditis?
Do you pursue coronary artery calcium scoring in patients with metabolic risk factors and autoimmune disease in order to guide decisions regarding GLP-1 medications?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
How would you approach management of a patient with ankylosing spondylitis who was doing well on tofacitinib, but experienced a STEMI while on therapy?
How do you assess the potential role of obesity in driving inflammatory joint symptoms?
Are there certain disease domains in a patient with psoriatic arthritis that will make bimekizumab a particularly good option?
How would you manage active severe psoriasis in a patient planning pregnancy, who also has psoriatic arthritis with well-controlled joint symptoms on certolizumab pegol (anti-TNF therapy)?
Where do you anticipate using bimekizumab in your sequence of treatment options for a patient with psoriatic arthritis?
What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for the management of psoriasis and/or psoriatic arthritis?
